COVID-19: Melatonin as a potential adjuvant treatment

• Published in: Life sciences (1973) Vol. 250; pp. 117583 - 6
• Main Authors: Zhang, Rui, Wang, Xuebin, Ni, Leng, Di, Xiao, Ma, Baitao, Niu, Shuai, Liu, Changwei, Reiter, Russel J.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.06.2020; Elsevier BV; Published by Elsevier Inc
• Subjects: Acute Lung Injury - virology; acute respiratory distress syndrome; Adjuvant therapy; adjuvants; Adjuvants, Immunologic - therapeutic use; Anti-Inflammatory Agents - therapeutic use; Antioxidants - therapeutic use; anxiety; Attenuation; Betacoronavirus; clinical trials; Coronavirus infections; Coronavirus Infections - drug therapy; Coronavirus Infections - immunology; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Cytokine storm; Cytokines; Cytokines - immunology; death; distress; Humans; Immune response; Immunomodulation; Inflammation; Inflammation - drug therapy; lungs; Melatonin; Melatonin - therapeutic use; Orthocoronavirinae; Oxidation; Oxidation-reduction; pandemic; Pandemics; Pathogenesis; Pathogens; Pathology; Patients; Permeability; Pneumonia, Viral - drug therapy; Pneumonia, Viral - immunology; Respiratory diseases; Respiratory distress syndrome; Respiratory Distress Syndrome - virology; SARS-CoV-2; sedation; Viral diseases; Viruses; COVID-19; SARS-CoV-2; Melatonin; Cytokines; Immunomodulation; Oxidation-reduction

This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory...